EMA Authorised: Enhertu (trastuzumab deruxtecan) — Daiichi Sankyo Europe GmbH

View source ↗

Summary

EMA authorised Enhertu (trastuzumab deruxtecan) for breast neoplasms under conditional approval, with Daiichi Sankyo Europe GmbH as MAH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: Daiichi Sankyo Europe GmbH. Decision date: 25/06/2026. Conditional approval